Review



recombinant cd38  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems recombinant cd38
    Recombinant Cd38, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Recombinant+Human+CD38+Protein%2C+CF/us12391765-840-5-7
    Average 93 stars, based on 14 article reviews
    recombinant cd38 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD + decline
    Article Snippet: ADP-ribosylcyclase , Sigma Aldrich , Cat#A9106. .. Recombinant human CD38 , R & D Systems , Cat2404-AC-010. .. β-Nicotinamide mononucleotide (NMN) , Sigma Aldrich , Cat#N3501.

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min, and nicotinic acid at 2.04 min. For data shown in , samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 × 2.1 mm, Waters Corp) coupled to a QTRAP 500 mass spec (SCIEX), as described previously ( ). .. CD38 base-exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54–Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalog number RDS2404-AC), with activity of >2500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide to cyclic GDP ribose. ..

    Article Title: Retention of stress susceptibility in the mdx mouse model of Duchenne muscular dystrophy after PGC-1α overexpression or ablation of IDO1 or CD38.
    Article Snippet: To 50 μg protein samples in duplicate, 50 μM nicotinamide 1, N6-ethenoadenine dinucleotide (sc-215559; Santa Cruz Biotechnology) or 200 μM nicotinamide guanine dinucleotide (N5131; Sigma-Aldrich) were added as NAD+ analog substrates to measure CD38 hydrolase and cyclase activity, respectively. .. Recombinant human CD38 (2404-AC-010; R&D Systems) was tested alongside samples as a positive control, and matrix and substrate blanks were included. .. Fluorescent product formation was measured using a SpectraMax® iD3 Multi-Mode Microplate Reader (Molecular Devices) with an emission wavelength of 300 nm and an excitation wavelength of 410 nm.

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide.
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min and nicotinic acid at 2.04 min. Jo urn al Pr e-p roo f 12 For data shown in Fig. 4, samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 x 2.1 mm, Waters Corp., USA) coupled to a QTRAP 500 mass spec (SCIEX), as described previously (Kim et al., 2023). .. CD38 base exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54 – Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalogue number RDS2404-AC), with activity of >2,500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide (NGD+) to cyclic GDP-ribose. ..

    Activity Assay:

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min, and nicotinic acid at 2.04 min. For data shown in , samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 × 2.1 mm, Waters Corp) coupled to a QTRAP 500 mass spec (SCIEX), as described previously ( ). .. CD38 base-exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54–Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalog number RDS2404-AC), with activity of >2500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide to cyclic GDP ribose. ..

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide.
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min and nicotinic acid at 2.04 min. Jo urn al Pr e-p roo f 12 For data shown in Fig. 4, samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 x 2.1 mm, Waters Corp., USA) coupled to a QTRAP 500 mass spec (SCIEX), as described previously (Kim et al., 2023). .. CD38 base exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54 – Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalogue number RDS2404-AC), with activity of >2,500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide (NGD+) to cyclic GDP-ribose. ..

    In Vitro:

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min, and nicotinic acid at 2.04 min. For data shown in , samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 × 2.1 mm, Waters Corp) coupled to a QTRAP 500 mass spec (SCIEX), as described previously ( ). .. CD38 base-exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54–Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalog number RDS2404-AC), with activity of >2500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide to cyclic GDP ribose. ..

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide.
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min and nicotinic acid at 2.04 min. Jo urn al Pr e-p roo f 12 For data shown in Fig. 4, samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 x 2.1 mm, Waters Corp., USA) coupled to a QTRAP 500 mass spec (SCIEX), as described previously (Kim et al., 2023). .. CD38 base exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54 – Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalogue number RDS2404-AC), with activity of >2,500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide (NGD+) to cyclic GDP-ribose. ..

    Produced:

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min, and nicotinic acid at 2.04 min. For data shown in , samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 × 2.1 mm, Waters Corp) coupled to a QTRAP 500 mass spec (SCIEX), as described previously ( ). .. CD38 base-exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54–Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalog number RDS2404-AC), with activity of >2500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide to cyclic GDP ribose. ..

    Article Title: CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide.
    Article Snippet: Metabolites of interest eluted from this ingredient as follows: NR at 17.2 min, NaMN at 17.09 min, NMN at 17.3 min, NaR at 12.96 min, nicotinamide at 2.24 min and nicotinic acid at 2.04 min. Jo urn al Pr e-p roo f 12 For data shown in Fig. 4, samples were run on a 1260 Infinity LC system using an Amide XBridge BEH column (100 x 2.1 mm, Waters Corp., USA) coupled to a QTRAP 500 mass spec (SCIEX), as described previously (Kim et al., 2023). .. CD38 base exchange activity was assessed in vitro using recombinant human CD38 (UniProt P28907, Val54 – Ile300) corresponding to its extracellular domain, with a C-terminal 6xHis tag produced in NS0-derived mouse myeloma cell line from R&D Systems (catalogue number RDS2404-AC), with activity of >2,500 pmol/min/μg, as measured by its ability to convert nicotinamide guanine dinucleotide (NGD+) to cyclic GDP-ribose. ..

    Positive Control:

    Article Title: Retention of stress susceptibility in the mdx mouse model of Duchenne muscular dystrophy after PGC-1α overexpression or ablation of IDO1 or CD38.
    Article Snippet: To 50 μg protein samples in duplicate, 50 μM nicotinamide 1, N6-ethenoadenine dinucleotide (sc-215559; Santa Cruz Biotechnology) or 200 μM nicotinamide guanine dinucleotide (N5131; Sigma-Aldrich) were added as NAD+ analog substrates to measure CD38 hydrolase and cyclase activity, respectively. .. Recombinant human CD38 (2404-AC-010; R&D Systems) was tested alongside samples as a positive control, and matrix and substrate blanks were included. .. Fluorescent product formation was measured using a SpectraMax® iD3 Multi-Mode Microplate Reader (Molecular Devices) with an emission wavelength of 300 nm and an excitation wavelength of 410 nm.



    Similar Products

    recombinant hcd38  (Sino Biological)
    94
    Sino Biological recombinant hcd38
    Recombinant Hcd38, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Human+CD38+Protein+(His+Tag)%2C+Endotoxin-Free/pm41671333-174-19-21
    Average 94 stars, based on 1 article reviews
    recombinant hcd38 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    recombinant human cd38  (Sino Biological)
    94
    Sino Biological recombinant human cd38
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Recombinant Human Cd38, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Human+CD38+Protein/pmc12873297-366-31-34
    Average 94 stars, based on 1 article reviews
    recombinant human cd38 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    recombinant humancd38  (Sino Biological)
    94
    Sino Biological recombinant humancd38
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Recombinant Humancd38, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Human+CD38+Protein/pm41639073-372-28-30
    Average 94 stars, based on 1 article reviews
    recombinant humancd38 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    recombinant human cd38  (Creative BioMart)
    91
    Creative BioMart recombinant human cd38
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Recombinant Human Cd38, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Recombinant+Human+CD38%2C+Fc-tagged/us12528877-78-12-16
    Average 91 stars, based on 1 article reviews
    recombinant human cd38 - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    dual antigen binding plate elisa assay  (Creative BioMart)
    92
    Creative BioMart dual antigen binding plate elisa assay
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Dual Antigen Binding Plate Elisa Assay, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Recombinant+Human+CD38/us12528877-78-1-16
    Average 92 stars, based on 1 article reviews
    dual antigen binding plate elisa assay - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    human fc tagged cd38  (Creative BioMart)
    91
    Creative BioMart human fc tagged cd38
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Human Fc Tagged Cd38, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Recombinant+Human+CD38%2C+Fc-tagged/us12528877-175-8-11
    Average 91 stars, based on 1 article reviews
    human fc tagged cd38 - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    recombinant cd38  (R&D Systems)
    93
    R&D Systems recombinant cd38
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Recombinant Cd38, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Recombinant+Human+CD38+Protein%2C+CF/us12391765-840-5-7
    Average 93 stars, based on 1 article reviews
    recombinant cd38 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    human cd38  (R&D Systems)
    93
    R&D Systems human cd38
    A A schematic showing interaction between CLL1.CAR and <t>CD38.SSR.</t> CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).
    Human Cd38, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+cd38/Recombinant+Human+CD38+Protein%2C+CF/us12391765-913-0-5
    Average 93 stars, based on 1 article reviews
    human cd38 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A A schematic showing interaction between CLL1.CAR and CD38.SSR. CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).

    Journal: Nature Communications

    Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

    doi: 10.1038/s41467-025-65897-4

    Figure Lengend Snippet: A A schematic showing interaction between CLL1.CAR and CD38.SSR. CAR and SSR configurations are denoted on the right B Representative flow plots showing co-expression of CAR and SSRs on day7 post co-transduction (TD). SSR expression was measured by detection of a surrogate maker truncated NGFR. C Residual tumor counts after a 3-day culture of CD38+ Molm13 (AML) and CCRF-CEM (T-ALL) with non-transduced T cells (NT) or SSR T cells at an E:T ratio 1:4. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean+S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Histograms showing CLL1 and CD38 levels in indicated cell lines. E Residual tumor counts and T-cell expansion after a 3-day co-culture of Molm13 and CCRF-CEM with CAR T cells at a E:T ratio 1:4. Data represent 6 donors from 3 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). F Histograms showing CLL1 and CD38 levels in pre-sorted THP1 and CLL1-low THP1 post-sorting. G Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 6 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (*P < 0.05. ns, non-significant). H CD38 expression in the parental and knock-out line of Molm13. I Residual tumor counts and fold T-cell expansion after 3 day culture at a E:T ratio 1:4. Data represent 4 donors from 2 independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). (* P < 0.05, ** P < 0.01. ns, non-significant).

    Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

    Techniques: Expressing, Transduction, Co-Culture Assay, Knock-Out

    A Schematic illustration (left) and representative images (right) of calcium influx (green) in T cells (blue) at pre-contact or post-contact with Molm13 (red) over the indicated time course. B Calcium (Ca++) flux in T cells interacting with Molm13 over the indicated timepoints, and the mean area under the curve (AUC) for the initial 30 min post-contact. Each dot represents a single cell. Data include single cells (42 cells (NT), 34 cells (CAR), 30 cells (CAR + ΔSSR), 30 cells (CAR + SSR)) combined from 3 independent donors and experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Dot plots show mean + S.E.M. (* P < 0.05, ** P < 0.01, ns, non-significant). C Western blots showing the detection of phospho-proteins and GAPDH harvested from CAR or CAR.SSR T cells stimulated with plate-coated anti-CLL1 CAR antibody and recombinant CD38 at indicated time points. Data were repeated in three independent experiments using 3 donors. MW, molecular weight. D Densitometry analysis of pPLCγ1, pERK1/2 and pNF-KB normalized to GAPDH. E Schematic of an SSR construct containing a point mutation Y132F in the LAT endo-domain, and flow plots (bottom) showing the co-expression of CAR and SSR or SSR with Y132F on day 6 post transduction. F Residual tumor counts (left) and T-cell expansion normalized to day 0 (right) in a 3 day co-culture with Molm13. Data represent two independent experiments with 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ns, non-significant).

    Journal: Nature Communications

    Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

    doi: 10.1038/s41467-025-65897-4

    Figure Lengend Snippet: A Schematic illustration (left) and representative images (right) of calcium influx (green) in T cells (blue) at pre-contact or post-contact with Molm13 (red) over the indicated time course. B Calcium (Ca++) flux in T cells interacting with Molm13 over the indicated timepoints, and the mean area under the curve (AUC) for the initial 30 min post-contact. Each dot represents a single cell. Data include single cells (42 cells (NT), 34 cells (CAR), 30 cells (CAR + ΔSSR), 30 cells (CAR + SSR)) combined from 3 independent donors and experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Dot plots show mean + S.E.M. (* P < 0.05, ** P < 0.01, ns, non-significant). C Western blots showing the detection of phospho-proteins and GAPDH harvested from CAR or CAR.SSR T cells stimulated with plate-coated anti-CLL1 CAR antibody and recombinant CD38 at indicated time points. Data were repeated in three independent experiments using 3 donors. MW, molecular weight. D Densitometry analysis of pPLCγ1, pERK1/2 and pNF-KB normalized to GAPDH. E Schematic of an SSR construct containing a point mutation Y132F in the LAT endo-domain, and flow plots (bottom) showing the co-expression of CAR and SSR or SSR with Y132F on day 6 post transduction. F Residual tumor counts (left) and T-cell expansion normalized to day 0 (right) in a 3 day co-culture with Molm13. Data represent two independent experiments with 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ns, non-significant).

    Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

    Techniques: Western Blot, Recombinant, Molecular Weight, Construct, Mutagenesis, Expressing, Transduction, Co-Culture Assay

    A Representative flow plots showing expression of CD38 and CLL1 in PBMCs including CD14+ monocytes, CD3 + T cells, CD3-CD56 + NK cells and CD19 + B cells. B Residual PBMCs after a 24-h co-culture with autologous T cells at a 1:4 E:T ratio. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (** P < 0.01. ns, non-significant). C Quantification of a burst forming unit-erythroid (BFU-E) and colony forming unit-granulocyte/macrophage (CFU-GM) from hematopoietic stem cells/progenitors (HSPC) after 5-h co-culture of indicated CAR T cells with CD34+ cord blood cells at a E:T ratio 10:1, and expanded for 12 days in semi-solid methylcellulose. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Flow histograms show surface CLL1 and CD38 levels on AML blasts (CD33 + /CD34 + ) from the PBMCs collected from 2 patients (Pt1 and Pt2). E The residual AML blasts were detected at 24 h or 72 h after co-culture with CLL1 CAR T cells at a 1:1 E:T ratio. Data represent 3 independent donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons, or two-tailed, paired Student’s t test for CAR vs CAR + SSR in residual AML blasts from Pt2 at 72 h. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant).

    Journal: Nature Communications

    Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

    doi: 10.1038/s41467-025-65897-4

    Figure Lengend Snippet: A Representative flow plots showing expression of CD38 and CLL1 in PBMCs including CD14+ monocytes, CD3 + T cells, CD3-CD56 + NK cells and CD19 + B cells. B Residual PBMCs after a 24-h co-culture with autologous T cells at a 1:4 E:T ratio. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (** P < 0.01. ns, non-significant). C Quantification of a burst forming unit-erythroid (BFU-E) and colony forming unit-granulocyte/macrophage (CFU-GM) from hematopoietic stem cells/progenitors (HSPC) after 5-h co-culture of indicated CAR T cells with CD34+ cord blood cells at a E:T ratio 10:1, and expanded for 12 days in semi-solid methylcellulose. Data represent 4 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). D Flow histograms show surface CLL1 and CD38 levels on AML blasts (CD33 + /CD34 + ) from the PBMCs collected from 2 patients (Pt1 and Pt2). E The residual AML blasts were detected at 24 h or 72 h after co-culture with CLL1 CAR T cells at a 1:1 E:T ratio. Data represent 3 independent donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons, or two-tailed, paired Student’s t test for CAR vs CAR + SSR in residual AML blasts from Pt2 at 72 h. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant).

    Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

    Techniques: Expressing, Co-Culture Assay, Two Tailed Test

    A A schematic showing enhancement of cytotoxicity of survivin-specific TCR (Sur-TCR) by a CD38.SSR. B Representative flow plots showing co-expression of Sur-TCR and SSR on day 7 post-transduction (TD), and ( C ) expansion of TCR T cells derived from 3 HLA-A2- and 3 HLA-A2+ donors on day 10. Data represent 6 donors from two independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (ns, non-significant). D Histograms showing intracellular survivin, surface HLA-A2 and CD38 levels in leukemia cell lines BV173, THP1 and TALL1. E Residual tumor counts after a 3-day co-culture with Sur-TCR T cells at a 1:4 E:T ratio. Data represent 6 donors from two independent experiments in co-culture with BV173 and THP1, and 3 donors from one independent experiment in co-culture with TALL1. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). Percentages of ( F ) granzyme B/CD107a double positive T cells and ( G ) cytokine positive T cells after 4-h co-culture with indicated leukemia cells at 1:1 E:T ratio. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). H Schematic timeline of the mouse experiment. I Leukemia progression was monitored by bioluminescence. J Tumor burden AUC between day 0 and day 26. The data represent 5 mice in NT and 4 mice in for TCR, TCR.ΔSSR and TCR.SSR. P values were determined using one-way ANOVA with Dunnet’s correction for multiple comparisons compared to NT. Bar graphs show mean + S.E.M. (* P = 0.0394). K Overall mouse survival in the THP1 model (NT, n = 5, TCR, n = 5, TCR.ΔSSR, n = 5, TCR.SSR, n = 4). Statistical significance was determined by a log rank test. (* P = 0.0214).

    Journal: Nature Communications

    Article Title: Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

    doi: 10.1038/s41467-025-65897-4

    Figure Lengend Snippet: A A schematic showing enhancement of cytotoxicity of survivin-specific TCR (Sur-TCR) by a CD38.SSR. B Representative flow plots showing co-expression of Sur-TCR and SSR on day 7 post-transduction (TD), and ( C ) expansion of TCR T cells derived from 3 HLA-A2- and 3 HLA-A2+ donors on day 10. Data represent 6 donors from two independent experiments. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (ns, non-significant). D Histograms showing intracellular survivin, surface HLA-A2 and CD38 levels in leukemia cell lines BV173, THP1 and TALL1. E Residual tumor counts after a 3-day co-culture with Sur-TCR T cells at a 1:4 E:T ratio. Data represent 6 donors from two independent experiments in co-culture with BV173 and THP1, and 3 donors from one independent experiment in co-culture with TALL1. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). Percentages of ( F ) granzyme B/CD107a double positive T cells and ( G ) cytokine positive T cells after 4-h co-culture with indicated leukemia cells at 1:1 E:T ratio. Data represent 3 donors. P values were determined using one way ANOVA with Tukey’s correction for multiple comparisons. Bar graphs show mean + S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001. ns, non-significant). H Schematic timeline of the mouse experiment. I Leukemia progression was monitored by bioluminescence. J Tumor burden AUC between day 0 and day 26. The data represent 5 mice in NT and 4 mice in for TCR, TCR.ΔSSR and TCR.SSR. P values were determined using one-way ANOVA with Dunnet’s correction for multiple comparisons compared to NT. Bar graphs show mean + S.E.M. (* P = 0.0394). K Overall mouse survival in the THP1 model (NT, n = 5, TCR, n = 5, TCR.ΔSSR, n = 5, TCR.SSR, n = 4). Statistical significance was determined by a log rank test. (* P = 0.0214).

    Article Snippet: To investigate LAT downstream signaling, 1 × 10 6 CAR.SSR T cells were loaded into a well of a 24-well plate pre-coated with 0.3 μg anti-CLL1 CAR antibody and 1 μg recombinant human CD38 (Sino Biological, Cat: 10818) for 30 min on ice, followed by stimulation at 37 °C in a water bath for indicated time-points.

    Techniques: Expressing, Transduction, Derivative Assay, Co-Culture Assay